BOSTON (TheStreet) -- Investors seeking steady dividends coupled with inflation-beating share appreciation may want to consider big drugmakers' stocks. They're expected to have as yet unrecognized growth potential from emerging market demand.
Investors are discounting the potential profit contribution from emerging markets because of their recent economic volatility and investors focus on the more dominant U.S. market, while there is also a misperception that operating profit margins coming from such markets are too low to matter, wrote Damien Conover, a Morningstar drug industry analyst, in a research report. "We expect this discount will dissipate as emerging markets' economies stabilize and their sales contribution increases."
Conover estimates that sales from emerging markets will represent 26% of Big Pharma's total sales by 2015, up from 19% in 2011, aided by rapid wealth creation in emerging-market countries that will drive demand for branded pharmaceuticals and a shift in companies' revenue mix as patent losses in developed markets result in their decline as a percentage of total revenue.Conover cited seven top international drug-company stocks in his report, and they have dividend yields ranging from 2% for the German chemicals conglomerate Bayer (BAYRY) to 6% for drugmaker AstraZeneca (AZN). Here are summaries of the seven biggest international pharmaceutical companies' stocks, arranged in inverse order of the number of analysts' "buy" ratings:
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV